Trinidad Montero-Melendez

Summary

Affiliation: Queen Mary
Location: London, UK

Publications

  1. pmc Downstream gene activation of the receptor ALX by the agonist annexin A1
    Derek Renshaw
    William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK
    PLoS ONE 5:. 2010
  2. pmc Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function
    Davina H Rhodes
    Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, Illinois, USA
    Obesity (Silver Spring) 21:310-9. 2013
  3. pmc The calcitonin and glucocorticoids combination: mechanistic insights into their class-effect synergy in experimental arthritis
    Adam Al-Kashi
    The William Harvey Research Institute, Barts and the London School of Medicine, London, United Kingdom
    PLoS ONE 8:e54299. 2013
  4. pmc Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors
    T Montero-Melendez
    Barts and the London School of Medicine, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, EC1M 6BQ, London, UK
    Cell Death Differ 20:567-75. 2013
  5. pmc Cell surface-expressed phosphatidylserine as therapeutic target to enhance phagocytosis of apoptotic cells
    K Schutters
    Department of Biochemistry, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht 6200 MD, The Netherlands
    Cell Death Differ 20:49-56. 2013
  6. pmc Melanocortin receptors as novel effectors of macrophage responses in inflammation
    Hetal B Patel
    William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London London, UK
    Front Immunol 2:41. 2011
  7. pmc Annexin A1 N-terminal derived Peptide ac2-26 exerts chemokinetic effects on human neutrophils
    Jesmond Dalli
    William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London London, UK
    Front Pharmacol 3:28. 2012
  8. doi Actions of translocator protein ligands on neutrophil adhesion and motility induced by G-protein coupled receptor signaling
    Camila Bento de Lima
    Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil
    Biochem Biophys Res Commun 417:918-23. 2012
  9. doi Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics
    Sandrine Vessillier
    Bone and Joint Research Unit, William Harvey Research Institute, London, UK
    Ann Rheum Dis 71:143-9. 2012
  10. pmc The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties
    Trinidad Montero-Melendez
    The William Harvey Research Institute, Barts, and the London School of Medicine, Queen Mary University of London, London, United Kingdom
    Am J Pathol 179:259-69. 2011

Collaborators

  • M Perretti
  • Fulvio D'Acquisto
  • Søren Nielsen
  • Giamila Fantuzzi
  • Angel Gil
  • L J Schurgers
  • Yuti Chernajovsky
  • D V Krysko
  • Dianne Cooper
  • Trinidad Montero-Melendez
  • Hetal B Patel
  • T Montero-Melendez
  • Jesmond Dalli
  • K Schutters
  • Adam Al-Kashi
  • Davina H Rhodes
  • Sandrine Vessillier
  • Camila Bento de Lima
  • Michael Seed
  • Derek Renshaw
  • Jeffrey C Jerman
  • Debra L Taylor
  • Jennifer M Cook
  • Rachel A E Forfar
  • José María Vieites
  • Maria Pini
  • C P M Reutelingsperger
  • D H M Kusters
  • P Vandenabeele
  • N M Deckers
  • J Dalli
  • Karla J Castellanos
  • James P Gilligan
  • Nozer Mehta
  • Niloufar Moradi-Bidhendi
  • M L L Chatrou
  • M Donners
  • Regina P Markus
  • Sandra Helena Poliselli Farsky
  • Trindad Montero-Melendez
  • Rita Jones
  • Simon McArthur
  • Gill Adams
  • João Palermo-Neto
  • Eduardo K Tamura
  • Karin V Greco
  • Thomas E N Jonassen
  • Ahmad Kamal
  • Trinidad Montero Melendez
  • Giovanna Leoni
  • Vincenzo Brancaleone
  • Andre L F Sampaio
  • Giuseppe Cirino
  • Raul de la Torre
  • Trinidad Montero
  • Antonio Sánchez-Pozo
  • María Angeles Ortega
  • Antonio Suarez
  • Jose María Peco

Detail Information

Publications17

  1. pmc Downstream gene activation of the receptor ALX by the agonist annexin A1
    Derek Renshaw
    William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK
    PLoS ONE 5:. 2010
    ..Here, we have focussed on the glucocorticoid modulated pro-resolution factor annexin A1 (AnxA1), studying if its interaction with the ALX receptor would affect downstream genomic targets...
  2. pmc Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function
    Davina H Rhodes
    Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, Illinois, USA
    Obesity (Silver Spring) 21:310-9. 2013
    ..Galectins (Gal) exert many activities, including regulation of inflammation and adipogenesis. We evaluated modulation of Gal-1, -3, -9 and -12 in visceral (VAT) and subcutaneous (SAT) adipose tissue in mice...
  3. pmc The calcitonin and glucocorticoids combination: mechanistic insights into their class-effect synergy in experimental arthritis
    Adam Al-Kashi
    The William Harvey Research Institute, Barts and the London School of Medicine, London, United Kingdom
    PLoS ONE 8:e54299. 2013
    ..Here we focus on the pairing of elcatonin (eCT) and dexamethasone (Dex), querying whether: i) this was a class-effect action; ii) mechanistic insights could be unveiled; iii) the synergy affected canonical GC adverse effects...
  4. pmc Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors
    T Montero-Melendez
    Barts and the London School of Medicine, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, EC1M 6BQ, London, UK
    Cell Death Differ 20:567-75. 2013
    ..We propose non-genomic modulation of AnxA1 in immune cells as a novel mechanism of action for HDACIs, which may underlie their reported efficacy in models of chronic inflammatory pathologies...
  5. pmc Cell surface-expressed phosphatidylserine as therapeutic target to enhance phagocytosis of apoptotic cells
    K Schutters
    Department of Biochemistry, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht 6200 MD, The Netherlands
    Cell Death Differ 20:49-56. 2013
    ..We conclude that targeting cell surface-expressed PS is an attractive strategy for treatment of inflammatory diseases and that the rationally designed RGD-anxA5 is a promising therapeutic agent...
  6. pmc Melanocortin receptors as novel effectors of macrophage responses in inflammation
    Hetal B Patel
    William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London London, UK
    Front Immunol 2:41. 2011
    ..The overall outcome will be identification of selective MC agonists as a strategy for innovative anti-inflammatory therapeutics...
  7. pmc Annexin A1 N-terminal derived Peptide ac2-26 exerts chemokinetic effects on human neutrophils
    Jesmond Dalli
    William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London London, UK
    Front Pharmacol 3:28. 2012
    ..We postulate that the generation of Annexin A1 N-terminal peptides at the site of inflammation may expedite the egress of migrated leukocytes thus promoting the return to homeostasis...
  8. doi Actions of translocator protein ligands on neutrophil adhesion and motility induced by G-protein coupled receptor signaling
    Camila Bento de Lima
    Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil
    Biochem Biophys Res Commun 417:918-23. 2012
    ..Taken together, these data highlight TSPO as a modulator of pathways of neutrophil adhesion and locomotion induced by GPCR, connecting TSPO actions and the onset of an innate inflammatory response...
  9. doi Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics
    Sandrine Vessillier
    Bone and Joint Research Unit, William Harvey Research Institute, London, UK
    Ann Rheum Dis 71:143-9. 2012
    ..This design improves efficacy, overcoming the limitations to their clinical use...
  10. pmc The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties
    Trinidad Montero-Melendez
    The William Harvey Research Institute, Barts, and the London School of Medicine, Queen Mary University of London, London, United Kingdom
    Am J Pathol 179:259-69. 2011
    ..These findings might clarify the tissue-protective properties of AP214 in clinical settings and may open further development for novel MC agonists...
  11. doi Role of melanocortin receptors in the regulation of gouty inflammation
    Trinidad Montero-Melendez
    William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Curr Rheumatol Rep 13:138-45. 2011
    ....
  12. doi Melanocortin control of cell trafficking in vascular inflammation
    Hetal B Patel
    The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ
    Adv Exp Med Biol 681:88-106. 2010
    ....
  13. ncbi Characterization of human cd200 glycoprotein receptor gene located on chromosome 3q12-13
    José María Vieites
    Department of Biochemistry and Molecular Biology, University of Granada, 18071 Granada, Spain
    Gene 311:99-104. 2003
    ..By RT-PCR, we have analyzed the expression of the four transcript variants in human placenta, spleen, liver, brain and kidney...
  14. pmc Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3
    Trinidad Montero-Melendez
    The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
    Cell Mol Life Sci . 2016
    ..In addition, MC3 PAMs emerged as a viable approach to the development of innovative therapeutics for joint diseases...
  15. doi ACTH: The forgotten therapy
    Trinidad Montero-Melendez
    The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, EC1M 6BQ, London, United Kingdom Electronic address
    Semin Immunol 27:216-26. 2015
    ....
  16. doi Connections in pharmacology: innovation serving translational medicine
    Trinidad Montero-Melendez
    The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK Electronic address
    Drug Discov Today 19:820-3. 2014
    ..We, pharmacologists of the third millennium, must aim towards maximising knowledge in an unbiased and cost-effective manner, to deliver new drugs for the global benefit of patients...
  17. doi Gapdh gene expression is modulated by inflammatory arthritis and is not suitable for qPCR normalization
    Trinidad Montero-Melendez
    The William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
    Inflammation 37:1059-69. 2014
    ....